Tuberculosis in solid-organ transplant recipients: Consensus statement of the Group for the Study of Infection in transplant recipients (GESITRA) of the Spanish society of infectious diseases and clinical microbiology

Clinical Infectious Diseases

Volumn 48, Issue 9, 2009, Pages 1276-1284

  Aguado, Josemaria ^a   Torre Cisneros, Julian ^d   Fortun, Jesus ^b   Benito, Natividad ^e   Meije, Yolanda ^a   Doblas, Antonio ^d   Munoz, Patricia ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; ETHAMBUTOL; EVEROLIMUS; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; PYRAZINAMIDE; PYRIDOXINE; QUINOLONE; QUINOLONE DERIVATIVE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN; T LYMPHOCYTE ANTIBODY; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; TUBERCULOSTATIC AGENT;

CLONAL ANERGY; DRUG TOLERANCE; EMERGENCY TREATMENT; GRAFT RECIPIENT; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUNG TRANSPLANTATION; ORGAN DONOR; ORGAN TRANSPLANTATION; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT INDICATION; TUBERCULIN TEST; TUBERCULOSIS; ARTICLE; DRUG INTERACTION; MORTALITY; PRACTICE GUIDELINE; SPAIN; TRANSPLANTATION;

ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RIFAMPIN; SPAIN; TRANSPLANTATION; TUBERCULOSIS;

EID: 65549101056     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597590     Document Type: Review

References (53)

1. Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplantation 1997; 63:1278-86.
2. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40:581-7.
3. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid- organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27:1266-77.
4. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 2004; 4(Suppl 10):37-41.
5. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001;32:851-4.
6. Gross PA, Barrett TL, Dellinger P, et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 1994; 18:421.
7. Basiri A, Hosseini Moghaddam SMM, Simforoosh N, et al. Preliminary report of nationwide case-control study for identifying risk factors of tuberculosis following renal transplantation. Transplant Proc 2005;37: 3041-4.
8. Torres J, Aguado JM, San Juan R, et al. Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation. Transpl Int 2008; 21:873-8.
9. John GT, Shankar V, Abraham AM, Mukundan U, Thomas PP, Jacob CK. Risk factors for post-transplant tuberculosis. Kidney Int 2001 ;60: 1148-53.
10. Benito N, Sued O, Moreno A, et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002; 74:1381-6.
11. Ayats-Ardite J, Cisneros-Herreros JM, Perez-Saenz JL, et al. Infectious disease assessment in solid organ transplant candidates [in Spanish]. Enferm Infecc Microbiol Clin 2002; 20:448-61.
12. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 2004; 4(Suppl 10):164-6.
13. Targeted tuberculin testing and treatment of latent tuberculosis infection. Statement of the ATS and the CDC. Am J Respir Crit Care Med 2000; 161:S221-47.
14. Kiuchi T, Inomata Y, Uemoto SA, et al. Hepatic graft tuberculosis transmitted from a living-related donor. Transplantation 1997;63: 905-7.
15. Torre-Cisneros J, Caston JJ, Moreno J, et al. Tuberculosis in the transplant candidate: importance of the early diagnosis and treatment. Transplantation 2004;77:1376-80.
16. Blanes M, Pumarola T. Evaluacion de la infecckm en el donante y receptor de organo solido. In: Aguado JM, ed. Infecciones en pacientes trasplantados. 2nd ed. Madrid: Elsevier, 2004:191-211.
17. Criterios de selecckm del donante de organos respecto a la transmi- sion de infecciones. Documento de consenso ONT-GESITRA. 2nd ed. November 2004. Available at: http://www.seimc.org/grupos/gesitra/ fuentes/gesitra-dyc103.pdf. Accessed 19 March 2009.
18. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
19. Graham JC, Kearns AM, Magee JG, et al. Tuberculosis transmitted through transplantation. J Infect 2001; 43:251.
20. Hernandez-Hernandez E, Alberu J, Gonzalez-Michaca L, Bobadilla-del Valle M, Correa-Rotter R, Sifuentes-Osornio J. Screening for tuberculosis in the study of the living renal donor in a developing country. Transplantation 2006;81:290-2.
21. Munoz P, Palomo J, Munoz R, Rodriguez-Creixems M, Pelaez T, Bouza E. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995;21: 398-402.
22. Riska H, Gronhagen-Riska C, Ahonen J. Tuberculosis and renal allo- graft transplantation. Transplant Proc 1987; 19:4096-7.
23. John GT, Thomas PP, Thomas M, Jeyaseelan L, Jacob CK, Shastry JC. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation 1994;57: 1683-4.
24. Varela A, Alvarez Kindelan A, Roman A, Ussetti P, Zurbano F. Tras- plante pulmonar. Grupo de Trabajo de la SEPAR (Guias de la Sociedad Espanola de Patologia del Aparato Respiratorio). Arch Bronconeumol 2001;37:307-15.
25. EBPG Expert Group in Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.2. Late infections. Tuberculosis. Nephrol Dial Transplant 2002; 17(Suppl 4):39-3.
26. Roman A, Bravo C, Levy G, et al. Isoniazid prophylaxis in lung transplantation. J Heart Lung Transplant 2000; 19:903-6.
27. Vikrant S, Agarwal SK, Gupta S, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis 2005; 7:99-108.
28. Agarwal SK, Gupta S, Dash SC, Bhowmik D, Tiwari SC. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. Int Urol Nephrol 2004; 36:425-31.
29. Lui SL, Li FK, Choy BY, Chan TM, Lo WK, Lai KN. Long-term outcome of isoniazid prophylaxis against tuberculosis in Chinese renal transplant recipients. Transpl Infect Dis 2004; 6:55-6.
30. Antony SJ, Ynares C, Dummer JS. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transplant 1997; 11:34-7.
31. Sud K, Muthukumar T, Singh B, et al. Isoniazid does not affect bio- availability of cyclosporine in renal transplant recipients. Methods Find Exp Clin Pharmacol 2000; 22:647-9.
32. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1-51.
33. Horsburgh CR Jr, Feldman S, Ridzon R. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 2000; 31:633-9.
34. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-7.
35. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002; 74:892-5.
36. Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases SocietyofAmerica. MMWRRecomm Rep 2005;54:1-81.
37. Sayiner A, Ece T, Duman S, et al. Tuberculosis in renal transplant recipients. Transplantation 1999; 68:1268-71.
38. al-Sulaiman MH, Dhar JM, al-Khader AA. Successful use ofrifampicin in the treatment of tuberculosis in renal transplant patients immu- nosuppressed with cyclosporine. Transplantation 1990; 50:597-8.
39. Dromer C, Nashef SA, Velly JF, Martigne C, Couraud L. Tuberculosis in transplanted lungs. J Heart Lung Transplant 1993; 12:924-7.
40. Offermann G, Keller F, Molzahn M. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5:385-7.
41. Lopez-Montes A, Gallego E, Lopez E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis 2004;44: e59-63.
42. Lee J, Yew WW, Wong CF, Wong PC, Chiu CS. Multidrug-resistant tuberculosis in a lung transplant recipient. J Heart Lung Transplant 2003;22:1168-73.
43. Vandevelde C, Chang A, Andrews D, Riggs W, Jewesson P. Rifampin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy 1991; 11:88-9.
44. O'Brien RJ. Development of fluoroquinolones as first-line drugs for tuberculosis-at long last! Am J Respir Crit Care Med 2003;168: 1266-8.
45. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3:432-42.
46. Lou HX, Shullo MA, McKaveney TP. Limited tolerability of levoflox- acin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy 2002;22: 701-4.
47. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56: 180-5.
48. Schluger LK, Sheiner PA, Jonas M, et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996; 63:364-9.
49. Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents: cure of disseminated infection with nonconventional regimens. Transplantation 2000; 69:64-9.
50. Kunimoto D, Warman A, Beckon A, Doering D, Melenka L. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hep- atotoxicity. Clin Infect Dis 2003; 36:e158-61.
51. Miro JM, Torre-Cisneros J, Moreno A, et al. Documento de consenso GESIDA/GESITRA-SEIMC, SPNS y ONT sobre trasplante de organo solido en pacientes infectados por el VIH en Espana (marzo 2005). Enferm Infecc Microbiol Clin 2005; 23:353-62.
52. Miro JM, Agilero F, Laguna M, et al. Liver transplantation in HIV/ hepatitis co-infection. J HIV Ther 2007; 12:24-35.
53. Park YS, Choi JY, Cho CH, et al. Clinical outcomes of tuberculosis in renal transplant recipients. Yonsei Med J 2004; 45:865-72.